Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
暂无分享,去创建一个
S. Schuetze | I. Judson | P. Haluska | A. Gualberto | F. Worden | D. Olmos | S. Okuno | J. D. de Bono | S. Postel-Vinay | M. L. Paccagnella | D. Yin | M. Scurr | L. R. Molife | K. Pritchard-Jones | G. Batzel | K. Pritchard‐Jones